Method and compositions for direct concentrated delivery of passive immunity

• US 5,718,899 A
• Filed: 02/29/1996
• Issued: 02/17/1998
• Est. Priority Date: 01/12/1993
• Status: Expired due to Fees

• Current Assignee: London Health Sciences Centre Research Incorporated
• Original Assignee: Anthony George Gristina, Quentin Newell Myrvik
• Inventors: Myrvik, Quentin Newell, Gristina, Anthony George
• Primary Examiner(s): LORING, SUSAN
• Application Number:
  US08/608,817
• Time in Patent Office: 719 Days
• Field of Search: 424/164.1, 424/150.1, 424/130.1, 424/163.1, 424/165.1, 424/169.1, 424/170.1, 530/387.1, 530/388.1, 530/388.2, 530/388.4, 530/389.1, 530/389.5
• US Class Current: 424/164.1
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 39/44 Antibodies bound to carriers
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 27/16 Otologicals
• CPC Class Codes: C07K 16/12 against material from bacteria
• CPC Class Codes: C07K 16/1214 from Pseudomonadaceae (F)
• CPC Class Codes: C07K 16/1271 from Micrococcaceae (F), e.g. Staphylococcus
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Compositions containing a high concentration of the full repertoire of immunoglobulins, including IgA, IgM and IgG, are used to combat infections from microorganisms and viruses at a wound, surgical, or burn site, or normal tissue at times of risk of infection. The compositions can contain elevated antibody titers for several specific pathogens including S. aureus, CNS, Enterococci, S. epidermidis, P. aeruginosa, E. coli, and Enterobacter spp., etc. The compositions are applied directly to a wound or burn site as an ointment, creme, fluid, spray, or the like, prior to vital or bacterial attachment or biofilm formation such that adhesion of the pathogens is inhibited and the pathogens closest to the wound or burn site will be pre-opsonized for phagocytic killing prior to toxin release. The immunoglobulins in the composition can be immobilized on a biocompatible material such as collagen, fibrin, hyaluronan, biodegradable polymers, and fragments thereof, which will be placed in-situ at the wound, surgical or burn site. In addition, the immunoglobulins in the composition may be coated on the body contacting surface of an implantable device such as a catheter, contact lens or total joint. The inventive compositions have particular application in preventing infections.

Claims

1. A method for preventing infections in human and animal hosts that are derived from implanted biomaterials, comprising the steps of:

coating a biomaterial to be implanted in a human or animal host with an antimicrobial composition containing 0.1-20% by weight of a mixture of antibodies within a pharmaceutically acceptable carrier wherein said mixture of antibodies is selected from the group consisting of IgG, IgG in combination with IgM and IgA, IgG in combination with monoclonal antibodies, IgG in combination with IgM and IgA and monoclonal antibodies, and monoclonal antibodies;

implanting said biomaterial in said human or animal host at a biomaterial implant site, said antimicrobial composition coated on said biomaterial producing an immunocompetent inflammatory zone sufficient to prevent adhesion of microorganisms to said biomaterial and to pre-opsonize said microorganisms for rapid intracellular killing by host defense mechanisms, said step of coating being performed prior to said step of implanting or within a period of six hours after implanting; and

preventing or reducing infections in said human or animal host at said biomaterial implant site with said antimicrobial composition.

2. The method of claim 1 further comprising the step of selecting said biomaterial to be a catheter.

3. The method of claim 1 further comprising the step of selecting said biomaterial to be a joint.

4. The method of claim 1 further comprising the step of selecting said biomaterial to be an articial heart.

5. The method of claim 1 further comprising the step of selecting said biomaterial to be a vascular graft.

6. The method of claim 1 further comprising the step of selecting said biomaterial to be a ventilator.

7. A method for preventing infections in human and animal hosts that are derived from implanted biomaterials, comprising the steps of:

coating a biomaterial to be implanted in a human or animal host with an antimicrobial composition containing IgG at a concentration ranging from 500-20,000 mg/dl;

implanting said biomaterial in said human or animal host at a biomaterial implant site, said antimicrobial composition coated on said biomaterial producing an immunocompetent inflammatory zone sufficient to prevent adhesion of microorganisms to said biomaterial and to pre-opsonize said microorganisms for rapid intracellular killing by host defense mechanisms, said step of coating being performed prior to said step of implanting or within a period of six hours after implanting; and

preventing or reducing infections in said human or animal host at said biomaterial implant site with said antimicrobial composition.

8. The method of claim 7 further comprising the step of selecting said biomaterial to be a catheter.

9. The method of claim 7 further comprising the step of selecting said biomaterial to be a joint.

10. The method of claim 7 further comprising the step of selecting said biomaterial to be an articial heart.

11. The method of claim 7 further comprising the step of selecting said biomaterial to be a ventilator.

12. The method of claim 7 further comprising the step of selecting said biomaterial to be a vascular graft.